On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24. 1% increase in total visits, the 32 urologists in our practice completed 16. 4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = . 017) and 21. 4% fewer prostate biopsies (42 fewer biopsies per month; P = . 001) in the 2 years following the USPSTF grade D recommendation.
Reviews in urology. 2015 [Epub]
Kathleen F McGinley, Gregory C McMahon, Gordon A Brown
Department of Urology, Rowan University School of Osteopathic Medicine, Stratford, NJ.